All In Biotech

Drug Trial Radar · NCT03728634

Evaluate the Safety and Tolerability, as Well as the Pharmacokinetic and Pharmacodynamic Profiles of Single and Multiple Doses of Eplontersen Administered Subcutaneously to Healthy Volunteers and Patients With Hereditary Transthyretin-Mediated Amyloidosis (hATTR ).

This Was a Phase 1/2, Double-blind, Randomized, Placebo-controlled, Dose-escalation Study Conducted at a Single Center for the Healthy Volunteer Cohorts in up to 56 Participants. It Consisted of 1 Single-dose Cohort and 3 Multiple-dose Cohorts (n = 12 Per Cohort, 10 Active:2 Placebo). The Open-label, hATTR Patient Cohort Portion of the Study Was Conducted at Multiple Centers.

Last checked: Nov 20, 2026Latest source record: Dec 19, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

47

Actual

Start

Dec 21, 2018

Primary completion

Feb 20, 2020

Study completion Feb 20, 2020

Sponsor

Lead sponsor
Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals (IONS)
Sponsor type
Industry
First posted
Nov 2, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To evaluate the safety and tolerability, as well as the pharmacokinetic and pharmacodynamic profiles of single and multiple doses of Eplontersen administered subcutaneously to healthy volunteers and patients with Hereditary Transthyretin-Mediated Amyloidosis (hATTR ).

Conditions

  • Healthy Volunteers
  • hATTR Amyloidosis

Interventions

  • ION-682884Drug

    ION-682884 administered SC

  • PlaceboDrug

    Placebo comparator calculated volume to match ION-682884 administered SC

  • Vitamin ADietary supplement

    Oral supplement

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With at Least One Treatment-Emergent Adverse Event (TEAE)Time frame: Up to Day 176
  2. Percentage of Participants Using Concomitant MedicationsTime frame: Up to Day 176
  3. Number of Participants With Clinically Significant Laboratory ValuesTime frame: Up to Day 176
  4. Number of Participants With Clinically Significant Physical Examination FindingsTime frame: Up to Day 176
  5. Number of Participants With Clinically Significant Electrocardiogram (ECG) ValuesTime frame: Up to Day 176

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Bio Pharma Services, Inc.

    Toronto, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.